Triple

T21169421
Position Surface form Disambiguated ID Type / Status
Subject Collegiate Inventors Competition E521654 entity
Predicate sponsor P67 FINISHED
Object AbbVie NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: AbbVie | Statement: [Collegiate Inventors Competition, sponsor, AbbVie]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: AbbVie
Context triple: [Collegiate Inventors Competition, sponsor, AbbVie]
  • A. AbbVie chosen
    AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
  • B. Pfizer
    Pfizer is a major American multinational pharmaceutical and biotechnology corporation known for developing a wide range of prescription medicines and vaccines, including one of the first widely used COVID-19 vaccines.
  • C. Abbott Laboratories
    Abbott Laboratories is a global healthcare company that develops and manufactures medical devices, diagnostics, branded generic medicines, and nutritional products.
  • D. Novartis
    Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
  • E. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b50e30748190b186824a206d39b9 completed April 16, 2026, 10:08 a.m.
NER Named-entity recognition batch_69e72711be9481909f16107b71d3500a completed April 21, 2026, 7:28 a.m.
Created at: April 16, 2026, 3 p.m.